 Enrollment completed and dosing resumed in the ongoing Phase 2 REVIVE study Resumption of rusfertide administration after suspension restored therapeutic benefits including hematocrit control, reduced red blood cell count, and decreased phlebotomy rate NEWARK, Calif., May 26, 2022 PRNewswire -- Protagonist Therapeutics Nasdaq: PTGX today announced new data from its ongoing Phase 2 REVIVE study evaluating rusfertide in patients with polycythemia vera PV. 